Holly Schroeder, PhD
About Holly Schroeder, PhD
Holly Schroeder, PhD, is a scientist specializing in non-viral research and development for gene editing at Asklepios BioPharmaceutical, Inc. She has extensive experience in lipid nanoparticle formulation and a strong background in immunology and pharmacoengineering.
Work at Asklepios BioPharmaceutical
Holly Schroeder, PhD, currently serves as a Scientist in Non-Viral R&D, Gene Editing at Asklepios BioPharmaceutical, Inc. (AskBio) since 2022. In this role, she leads the development of lipid nanoparticle formulations for therapeutic candidate selection within a flagship gene editing program. Prior to her current position, she worked as a Translational Scientist at AskBio from 2019 to 2021, focusing on immunology. Her extensive experience at AskBio highlights her commitment to advancing gene editing technologies.
Education and Expertise
Holly Schroeder earned her Doctor of Philosophy (Ph.D.) in Pharmacoengineering and Molecular Pharmaceutics from the University of North Carolina at Chapel Hill, where she studied from 2013 to 2018. She also holds a Bachelor of Arts (BA) in Biochemistry and Spanish from Lawrence University. Her expertise includes non-viral delivery systems, particularly lipid nanoparticles, which are crucial for gene therapy applications. This educational background supports her research and development efforts in gene editing.
Professional Background
Holly Schroeder has a diverse professional background in the field of biomedical research. She began her career as a Research Technician at Northwestern University, Feinberg School of Medicine, from 2011 to 2013. She then transitioned to the UNC Eshelman School of Pharmacy, where she served as a Clinical Study Coordinator from 2014 to 2017. Following this, she worked as a Research Fellow at Parion Sciences for a brief period in 2017 before returning to Asklepios BioPharmaceutical as a Translational Scientist.
Research Contributions
Throughout her career, Holly Schroeder has contributed to various research initiatives in gene editing and immunology. At Asklepios BioPharmaceutical, she has specialized in a novel nuclease system for gene editing applications. Her work in developing lipid nanoparticle formulations has been pivotal in advancing therapeutic candidate selection, showcasing her role in innovative research within the biotechnology sector.